Determination of trimethoprim and sulphadoxine residues in porcine tissues and plasma.
Healthy gilts and market-ready hogs were administered a single intramuscular (IM) injection of Borgal, a commercial formulation of trimethoprim-sulfadoxine (TMP-SDX), once or twice daily. The objectives were to determine if a newly-developed high-performance liquid chromatographic (HPLC) method would be suitable for measuring the residual concentrations of TMP in the plasma of these live animals, and to determine if the administration of this veterinary drug would leave measurable residues in their plasma and tissues at slaughter. Plasma and tissue concentrations of SDX and TMP from these animals were determined over a period of 14 d using thin-layer chromatography/densitometry (TLCD), and the newly-developed HPLC method, respectively. The lowest detectable limit (LDL) for SDX in plasma and tissue was 20 ppb by TLCD. The HPLC method had a LDL of 5 ppb for TMP in plasma and tissue. Both methods were then used to provide baseline data on the absorption and depletion of TMP and SDX from these healthy animals. It was observed that both TMP and SDX were readily absorbed into the blood and tissues, but TMP was eliminated much faster than SDX. No TMP residues were detected in the plasma of any of the gilts at and beyond 21 h after drug administration. Also, no TMP residues were detected in the plasma of any of the market-ready hogs 24 h after drug administration at either the label dose or twice the label dose. Sulfadoxine residues at concentrations above the maximum residue limit (MRL) of 100 ppb were, however, detected in the plasma, muscle, kidney, liver, and injection sites of hogs slaughtered 1 and 3 d after a single IM administration at the label dose. Although SDX residues were still detectable in the lungs, kidney, liver and plasma of some hogs 10 d after administration of the label dose and twice the label dose, these were below the MRL. Postmortem examination revealed necrosis and inflammation at the injection sites, but no visible deposits of the injected drug.
Boison
J O
JO
Health of Animals Laboratory, Agriculture and Agri-Food Canada, Saskatoon, Saskatchewan.
Nachilobe
P
P
Cassidy
R
R
Keng
L
L
Thacker
P A
PA
Peacock
A
A
Fesser
A C
AC
Lee
S
S
Korsrud
G O
GO
Bulmer
W S
WS
D000818:Animals; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000032:analysis* / Q000097:blood; D002851:Chromatography, High Pressure Liquid / Q000662:veterinary; D002855:Chromatography, Thin Layer / Q000662:veterinary; D005260:Female; D007273:Injections, Intramuscular; D007668:Kidney / Q000737:chemistry*; D008099:Liver / Q000737:chemistry*; D008168:Lung / Q000737:chemistry*; D018482:Muscle, Skeletal / Q000737:chemistry*; D013413:Sulfadoxine / Q000008:administration & dosage / Q000032:analysis* / Q000097:blood; D013424:Sulfanilamides / Q000008:administration & dosage / Q000032:analysis* / Q000097:blood; D013552:Swine / Q000378:metabolism*; D014295:Trimethoprim / Q000008:administration & dosage / Q000032:analysis* / Q000097:blood
D000892:Anti-Infective Agents, Urinary; D013424:Sulfanilamides; D013413:Sulfadoxine; D014295:Trimethoprim